Detailed company information
Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI). The company's pipeline further encompasses SER-155, a synthetically cultured bacterial formulation currently undergoing Phase Ib evaluation. This candidate aims to mitigate the risk of gastrointestinal and bloodstream infections, alongside graft-versus-host disease, in vulnerable patients undergoing allogeneic hematopoietic stem cell or solid organ transplantation. Additionally, Seres Therapeutics is advancing SER-287 and SER-301, both in Phase Ib for ulcerative colitis, as well as SER-401, which targets metastatic melanoma, and SER-262, also directed at Clostridioides difficile infection. Seres maintains strategic alliances through licensing and collaboration agreements with entities such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center. Established in 2010, the company previously operated as Seres Health, Inc. before adopting its current name in May 2015, and it maintains its principal offices in Cambridge, Massachusetts.
Last Updated: Sep 2026
Earnings Transcript for 2025 - Q3Released: Nov 05, 2025
Earnings Transcript for 2025 - Q2Released: Aug 06, 2025
Earnings Transcript for 2025 - Q1Released: May 07, 2025
Earnings Transcript for 2024 - Q4Released: Mar 13, 2025
Earnings Transcript for 2024 - Q3Released: Nov 13, 2024
Earnings Transcript for 2024 - Q2Released: Aug 13, 2024
Earnings Transcript for 2024 - Q1Released: May 08, 2024
Earnings Transcript for 2023 - Q4Released: Mar 05, 2024
Earnings Transcript for 2023 - Q3Released: Nov 04, 2023
Earnings Transcript for 2023 - Q2Released: Aug 08, 2023
Earnings Transcript for 2023 - Q1Released: May 09, 2023
Earnings Transcript for 2022 - Q4Released: Mar 07, 2023
Earnings Transcript for 2022 - Q3Released: Nov 02, 2022
Earnings Transcript for 2022 - Q2Released: Aug 03, 2022
Earnings Transcript for 2022 - Q1Released: May 04, 2022
Earnings Transcript for 2021 - Q4Released: Mar 01, 2022
Earnings Transcript for 2021 - Q3Released: Nov 10, 2021
Earnings Transcript for 2021 - Q2Released: Aug 03, 2021
Earnings Transcript for 2021 - Q1Released: May 04, 2021
Earnings Transcript for 2020 - Q4Released: Mar 02, 2021
Earnings Transcript for 2020 - Q3Released: Nov 09, 2020
Earnings Transcript for 2020 - Q1Released: May 10, 2020
Earnings Transcript for 2019 - Q4Released: Mar 02, 2020
Earnings Transcript for 2019 - Q3Released: Nov 05, 2019
Dafinchi
